| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases
|
Haghikia, Aiden
|
|
|
23 |
6 |
p. 615-624
|
artikel
|
| 2 |
Cerebral cavernous malformations: to operate or not?
|
Rinkel, Gabriël J E
|
|
|
23 |
6 |
p. 546-547
|
artikel
|
| 3 |
Climate change and disorders of the nervous system
|
Sisodiya, Sanjay M
|
|
|
23 |
6 |
p. 636-648
|
artikel
|
| 4 |
Correction to Lancet Neurol 2024; 23: 465–76
|
|
|
|
23 |
6 |
p. e10
|
artikel
|
| 5 |
Correction to Lancet Neurol 2024; 23: 393–403
|
|
|
|
23 |
6 |
p. e10
|
artikel
|
| 6 |
Elucidating a new path of CSF transport in the CNS
|
Benveniste, Helene
|
|
|
23 |
6 |
p. 553-554
|
artikel
|
| 7 |
Forging ahead in haemorrhagic stroke research
|
The Lancet Neurology,
|
|
|
23 |
6 |
p. 545
|
artikel
|
| 8 |
Haemorrhagic stroke and brain vascular malformations in women: risk factors and clinical features
|
Ali, Mariam
|
|
|
23 |
6 |
p. 625-635
|
artikel
|
| 9 |
Medical management and surgery versus medical management alone for symptomatic cerebral cavernous malformation (CARE): a feasibility study and randomised, open, pragmatic, pilot phase trial
|
|
|
|
23 |
6 |
p. 565-576
|
artikel
|
| 10 |
Negative findings from trials with NLY01 or deferiprone for Parkinson's disease
|
Müller, Thomas
|
|
|
23 |
6 |
p. 558-559
|
artikel
|
| 11 |
Negative findings from trials with NLY01 or deferiprone for Parkinson's disease – Author's reply
|
McGarry, Andrew
|
|
|
23 |
6 |
p. 559
|
artikel
|
| 12 |
Neurology and climate change
|
Junck, Larry
|
|
|
23 |
6 |
p. 552-553
|
artikel
|
| 13 |
New gene involved in the pathogenesis of Parkinson's disease
|
Toft, Mathias
|
|
|
23 |
6 |
p. 550-552
|
artikel
|
| 14 |
Pooja Khatri: driven by appreciation and gratitude
|
Venkatesan, Priya
|
|
|
23 |
6 |
p. 560
|
artikel
|
| 15 |
RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses
|
Gustavsson, Emil K
|
|
|
23 |
6 |
p. 603-614
|
artikel
|
| 16 |
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial
|
Cree, Bruce A C
|
|
|
23 |
6 |
p. 588-602
|
artikel
|
| 17 |
SARS-CoV-2 infection as a cause of neurodegeneration
|
Bonhenry, Daniel
|
|
|
23 |
6 |
p. 562-563
|
artikel
|
| 18 |
Speculation on the transmissibility of Alzheimer's disease
|
Kapasi, Alifiya
|
|
|
23 |
6 |
p. 555-556
|
artikel
|
| 19 |
Stopping haematoma growth: the search for the right time, place, and agent
|
Voigt, Sabine
|
|
|
23 |
6 |
p. 547-548
|
artikel
|
| 20 |
Targeting B cells in neuromyelitis optica spectrum disorder
|
Zhang, Chao
|
|
|
23 |
6 |
p. 549-550
|
artikel
|
| 21 |
The Egyptian origins of neuroanatomy
|
Drouin, Emmanuel
|
|
|
23 |
6 |
p. 561
|
artikel
|
| 22 |
The prescription of valproate: risk of harm
|
Cave, Alison
|
|
|
23 |
6 |
p. 557
|
artikel
|
| 23 |
The prescription of valproate: risk of harm
|
Rugg-Gunn, Fergus
|
|
|
23 |
6 |
p. 557-558
|
artikel
|
| 24 |
The torment of needing to know for sure
|
Lees, Andrew J
|
|
|
23 |
6 |
p. 564
|
artikel
|
| 25 |
Thien Phu Do
|
|
|
|
23 |
6 |
p. 561
|
artikel
|
| 26 |
Tranexamic acid versus placebo in individuals with intracerebral haemorrhage treated within 2 h of symptom onset (STOP-MSU): an international, double-blind, randomised, phase 2 trial
|
Yassi, Nawaf
|
|
|
23 |
6 |
p. 577-587
|
artikel
|
Tijdschrift beschrijving